Christer Lundell-Ek
Research Subjects
Christer Lundell-Ek has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Aase Wagner
Department of Neuroradiology, Copenhagen University Hospital, Rigshospitalet, 2100, Copenhagen, Denmark
1 shared publication- Alexei F. Kirkin
Danish Cancer Society Research Center, 2100, Copenhagen, Denmark.
1 shared publication - Christina Dahl
Molecular Diagnostics, Danish Cancer Institute, Copenhagen, Denmark
1 shared publication Helle Broholm
Department of Neuropathology, Copenhagen University Hospital, Rigshospitalet, 2100, Copenhagen, Denmark
1 shared publication- Henrik J. Ditzel
University of Southern Denmark
1 shared publication - Ian Law
Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark
1 shared publication
Latest Publications
- Open Access
- 6 March 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-12
Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells
In cancer cells, cancer/testis (CT) antigens become epigenetically derepressed through DNA demethylation and constitute attractive targets for cancer immunotherapy. Here we report that activated CD4+ T helper cells treated with a DNA-demethylating agent express a broad repertoire of endogenous CT antigens and can be used as antigen-presenting cells to generate autologous cytotoxic T lymphocytes (CTLs) and natural killer cells. In vitro, activated CTLs induce HLA-restricted lysis of tumor cells of different histological types, as well as cells expressing single CT antigens. In a phase 1 trial of 25 patients with recurrent glioblastoma multiforme, cytotoxic lymphocytes homed to the tumor, with tumor regression ongoing in three patients for 14, 22, and 27 months, respectively. No treatment-related adverse effects were observed. This proof-of-principle study shows that tumor-reactive effector cells can be generated ex vivo by exposure to antigens induced by DNA demethylation, providing a novel, minimally invasive therapeutic strategy for treating cancer.
- 6 March 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-12
Open AccessAdoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells
In cancer cells, cancer/testis (CT) antigens become epigenetically derepressed through DNA demethylation and constitute attractive targets for cancer immunotherapy. Here we report that activated CD4+ T helper cells treated with a DNA-demethylating agent express a broad repertoire of endogenous CT antigens and can be used as antigen-presenting cells to generate autologous cytotoxic T lymphocytes (CTLs) and natural killer cells. In vitro, activated CTLs induce HLA-restricted lysis of tumor cells of different histological types, as well as cells expressing single CT antigens. In a phase 1 trial of 25 patients with recurrent glioblastoma multiforme, cytotoxic lymphocytes homed to the tumor, with tumor regression ongoing in three patients for 14, 22, and 27 months, respectively. No treatment-related adverse effects were observed. This proof-of-principle study shows that tumor-reactive effector cells can be generated ex vivo by exposure to antigens induced by DNA demethylation, providing a novel, minimally invasive therapeutic strategy for treating cancer.